Share on LinkedInShare on LinkedIn

ARTICLE · 28 FEBRUARY 2023

A Split Decision On Patentability: What Worked For The Petitioner And What Did Not

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In Nanofiber Solutions, LLC v. Acera Surgical, Inc., IPR2021-01016, Paper 8 (P.T.A.B. Dec. 13, 2022), the Patent Trial and Appeal Board ("the Board") found claims 1, 2, 4-7, and 13 of Acera's

United StatesIntellectual Property

Holding

In Nanofiber Solutions, LLC v. Acera Surgical, Inc., IPR2021-01016, Paper 8 (P.T.A.B. Dec. 13, 2022), the Patent Trial and Appeal Board ("the Board") found claims 1, 2, 4-7, and 13 of Acera's US Pat. No. 10,632,228 ("the '228 patent") unpatentable. The Board also held that Nanofiber did not establish by a preponderance of the evidence that claims 3, 8-12, or 14-20 of the '228 patent are unpatentable.

Background

The '228 patent describes using non-woven graft materials, comprising at least two distinct fiber compositions, to repair tissue following surgical procedures. '228 patent at 1:6-13. The claims recite the use of poly(glycolic acid) (PGA) and poly(lactide-co-caprolactone) (PLCL) as the two fiber compositions. Id. at 19:45-46, 56-59.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from